The development of genomic tests and how validation affects their use in the clinic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains that the specific setting and utility of a tumour biomarker must be clearly defined during clinical investigation in order to generate meaningful results. In patients with early stage breast cancer, there is a need to identify new risk factors for disease outcome, which may enable the identification of patients who are likely to respond to specific therapies.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:
Color/Sound:

2015
03:33
Color/Sound

Comments are closed.